Tonix Pharmaceuticals Holding (TNXP) Stock Overview
A fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TNXP Community Fair Values
Create NarrativeSee what 68 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tonix Pharmaceuticals Holding Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.50 |
| 52 Week High | US$69.97 |
| 52 Week Low | US$9.40 |
| Beta | 1.69 |
| 1 Month Change | 13.02% |
| 3 Month Change | -20.58% |
| 1 Year Change | -79.02% |
| 3 Year Change | -99.58% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) just kicked off its latest quarterly results...Tonix Delivers A Beat, But The Real Test Starts Now
Summary Tonix Pharmaceuticals (TNXP) reported strong 2Q26 results, with $13.5M revenue and early commercial traction for TONMYA, but remains in a spend-to-scale phase. TONMYA prescriptions and refills surged, yet revenue lags due to recent payer coverage; sustained revenue ramp hinges on access translating to reimbursed sales. Operating expenses and cash burn are elevated, with a cash runway into early 2Q27, creating near-term dilution risk despite improving fundamentals. Valuation appears cheap on EV metrics, but equity pricing reflects execution and financing risks; clear proof of scalable, access-driven growth is needed before upgrading from Hold. Read the full article on Seeking Alpha
Fibromyalgia And Lyme Setbacks Will Pressure Margins Yet Long-Term Pipeline Potential Remains
Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding develops and commercializes medicines for conditions with unmet medical need, including fibromyalgia, major depressive disorder and Lyme disease prevention. What are the underlying business or industry changes driving this perspective?Recent updates
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Tonix Pharmaceuticals Holding Corp. ( NASDAQ:TNXP ) just kicked off its latest quarterly results...Tonix Delivers A Beat, But The Real Test Starts Now
Summary Tonix Pharmaceuticals (TNXP) reported strong 2Q26 results, with $13.5M revenue and early commercial traction for TONMYA, but remains in a spend-to-scale phase. TONMYA prescriptions and refills surged, yet revenue lags due to recent payer coverage; sustained revenue ramp hinges on access translating to reimbursed sales. Operating expenses and cash burn are elevated, with a cash runway into early 2Q27, creating near-term dilution risk despite improving fundamentals. Valuation appears cheap on EV metrics, but equity pricing reflects execution and financing risks; clear proof of scalable, access-driven growth is needed before upgrading from Hold. Read the full article on Seeking AlphaFibromyalgia And Lyme Setbacks Will Pressure Margins Yet Long-Term Pipeline Potential Remains
Catalysts About Tonix Pharmaceuticals Holding Tonix Pharmaceuticals Holding develops and commercializes medicines for conditions with unmet medical need, including fibromyalgia, major depressive disorder and Lyme disease prevention. What are the underlying business or industry changes driving this perspective?Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Here's Why We're Not Too Worried About Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Situation
NasdaqCM:TNXP 1 Year Share Price vs Fair Value Explore Tonix Pharmaceuticals Holding's Fair Values from the Community...Shareholder Returns
| TNXP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.3% | 4.5% | 1.0% |
| 1Y | -79.0% | 38.3% | 18.4% |
Return vs Industry: TNXP underperformed the US Biotechs industry which returned 38.3% over the past year.
Return vs Market: TNXP underperformed the US Market which returned 18.4% over the past year.
Price Volatility
| TNXP volatility | |
|---|---|
| TNXP Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TNXP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TNXP's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 142 | Seth Lederman | www.tonixpharma.com |
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Tonix Pharmaceuticals Holding Corp. Fundamentals Summary
| TNXP fundamental statistics | |
|---|---|
| Market cap | US$205.30m |
| Earnings (TTM) | -US$159.67m |
| Revenue (TTM) | US$29.10m |
Is TNXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TNXP income statement (TTM) | |
|---|---|
| Revenue | US$29.10m |
| Cost of Revenue | US$4.71m |
| Gross Profit | US$24.40m |
| Other Expenses | US$184.06m |
| Earnings | -US$159.67m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.31 |
| Gross Margin | 83.83% |
| Net Profit Margin | -548.64% |
| Debt/Equity Ratio | 0% |
How did TNXP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/13 21:46 |
| End of Day Share Price | 2026/08/13 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tonix Pharmaceuticals Holding Corp. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Chiara Russo | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |